Somagenetix Secures $11.7 Million in Series A Funding to Revolutionize Gene Therapy for Phagocyte Disorders

Exciting news in the world of gene therapy: Somagenetix, a pioneering spin-off from the University of Zurich, has successfully raised $11,700,000 in funding to propel its mission of delivering groundbreaking treatments for phagocyte-related disorders. With a specialized focus on immunodeficiency, neurodegeneration, and cancer with brain metastasis, Somagenetix aims to become a leader in the gene therapy landscape by harnessing the power of genetically enhanced phagocytes. The company’s state-of-the-art platform addresses the fundamental challenges of ex-vivo gene therapies, including specificity, long-term efficacy, and safety. Powered by a highly accomplished scientific team with over 17 years of experience in gene therapy research and clinical development, Somagenetix is uniquely positioned to tackle the unmet medical needs that plague patients suffering from these critical conditions. The newly acquired capital will be instrumental in advancing the company's innovative research and development initiatives, enabling them to conduct pivotal clinical trials and expedite the progression of their first-in-class therapies. Our unwavering commitment is to ensure that every patient with phagocyte disorders receives the care they need to achieve better health outcomes. As we look to the future, we are more determined than ever to make a significant impact in the field of gene therapy, transforming lives one treatment at a time. We invite our stakeholders and the broader community to join us on this transformative journey as we strive to cure diseases that have long been viewed as insurmountable challenges.